A Phase Ib Open Label Clinical Trial to Evaluate the Safety and Efficacy of ERAS-801 in Recurrent Glioblastoma or Elderly Newly Diagnosed Glioblastoma Patients With EGFR Amplification and/or Mutation (ERAS-801-3.0)

This study is testing an experimental drug called ERAS-801 for patients with specific types of aggressive brain cancer known as glioblastoma. The drug is designed to block a protein called EGFR, which can cause cancer cells to grow, and it is specifically made to reach the brain to help shrink or slow down these tumors.

You may be eligible if you are at least 18 years old and have a confirmed diagnosis of glioblastoma or gliosarcoma that has returned or is newly diagnosed in elderly patients. Your tumor must have specific genetic changes in the EGFR protein, and you must be healthy enough to undergo standard medical monitoring and imaging.

Participants will receive the experimental drug and undergo regular check-ups, including MRI and PET brain scans to monitor the tumor, heart ultrasounds, and blood tests. You may also undergo surgery to remove tumor tissue, which helps doctors analyze how the treatment is affecting the cancer cells.

This study is currently recruiting patients and is taking place in Los Angeles, California, and New York, New York.